Treatment of Persistent Barrett’s Esophagus with Salvage Cryotherapy
Keywords:
Cryotherapy, Radiofrequency ablation, Barrett’s esophagusAbstract
Background: A dysplastic Barrett’s esophagus can lead to cancer if not treated by endoscopic eradication therapy. The current consensus is to eradicate the entire residual Barrett’s esophagus that is visible during endoscopy by ablation therapy. However, a section of patients are resistant to this ablation therapy. They may need a second line of ablation therapy to eradicate the visible residual Barrett’s esophagus.
Aims: To evaluate the efficacy of treatment with salvage cryotherapy of persistent Barrett’s esophagus who failed to respond for ablation by radio frequency ablation.
Methods: Barrett’s esophagus with high-grade dysplasia was initially treated with radiofrequency ablation (RFA) for at least 6 sessions to achieve complete eradication of Barrett’s esophagus. Barrett’s esophagus patients who failed to respond to the radiofrequency ablation was then treated with a different ablation therapy modality like a cryotherapy to achieve complete eradication of Barrett’s esophagus.
Results: Two patients with Barrett’s esophagus and high-grade dysplasia were included in the case series. The Barrett’s esophagus in both the patients was treated with a mean of 6.5 sessions of radiofrequency ablation. Both the patients had persistent Barrett’s esophagus despite the treatment with radiofrequency ablation as demonstrated by surveillance endoscopic biopsies. They were then treated with a mean of 4.5 sessions of cryotherapy as a salvage therapy. Surveillance endoscopy showed persistent Barrett’s esophagus in both the patients despite being treated with cryotherapy. None of the patients had high-grade dysplasia in the surveillance endoscopy.
Conclusion: Salvage cryotherapy is futile in persistent Barrett’s esophagus that had prior treatment failure with a different ablation therapy.
References
Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna clas-sification of gastrointestinal epithelial neoplasia. Gut. 2000; 47: 251-255. doi: 10.1136/gut.47.2.251
Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of ad-enocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011; 365: 1375-1383. doi: 10.1056/NEJMoa1103042
Spechler SJ, Sharma P, Souza RF, et al. American gastroen-terological association technical review on the management of barrett’s esophagus. Gastroenterology. 2011; 140(3): e18-e13. doi: 10.1053/j.gastro.2011.01.031
Orman ES, Li N, Shaheen NJ. Efficacy and durability of Gastro Open J radiofrequency ablation for Barrett’s esophagus: Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013; 11(10): 1245-1255.
Saligram S, Chennat J, Hu H, et al. Endotherapy for super-ficial adenocarcinoma of the esophagus: An American experi-ence. Gastrointest Endosc. 2013; 77(6): 872-876. doi: 10.1016/j. gie.2013.01.014
Saligram S, Tofteland N, Wani S et al. Long-term results of the mucosal ablation of Barrett’s esophagus: Efficacy and recur-rence. Endosc Int Open. 2015; 3(3): E189-E194. doi: 10.1055/s-0034-1391669
Brown J, Alsop B, Gupta N et al. Effectiveness of focal vs. balloon radiofrequency ablation devices in the treatment of Bar-rett’s esophagus. United European Gastroenterol J. 2016; 4(2): 236-241. doi: 10.1177/2050640615594549
Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008; 57(9): 1200-1206. doi: 10.1136/gut.2007.142539
Halsey KD, Greenwald BD. Cryotherapy in the management of esophageal dysplasia and malignancy. Gastrointest Endosc Clin N Am. 2010; 20(1): 75-87. doi: 10.1016/j.giec.2009.07.009
Gosain S, Mercer K, Twaddell WS, et al. Liquid nitrogen spray cryotherapy in Barrett’s esophagus with high-grade dys-plasia: Long-term results. Gastrointest Endosc. 2013; 78(2): 260-265. doi: 10.1016/j.gie.2013.03.002
Sengupta N, Ketwaroo GA, Bak DM, et al. Salvage cryo-therapy after failed radiofrequency ablation for Barrett’s esoph-agus-related dysplasia is safe and effective. Gastrointest Endosc. 2015; 82(3): 443-448. doi: 10.1016/j.gie.2015.01.033
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Gastro (GOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.